Radient Pharmaceuticals Files Patents in Japan and China

Published: Oct 24, 2011

TUSTIN, CA--(Marketwire - October 24, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has filed patent applications for its proprietary Onko-Sure® cancer test with the patent offices of Japan and China. Patent protection enhances the Company's distribution channel opportunities in these countries. Filing international patent applications is part of Radient's global strategy to increase the number of markets in which Onko-Sure® is regulatory approved for various indications and patent protected.

"We have been selling Onko-Sure® in Asian countries where we are experiencing continued growth, with consistent re-orders from customers in the region. Japan and China are larger markets, where having patent protection improves our ability to forge productive distribution partnerships for our cancer test," stated Radient Chairman and CEO Douglas MacLellan.

Onko-Sure® is a non-invasive cancer blood test that has been shown, in a large body of published clinical research, to be effective in the detection and treatment monitoring of 19 different cancers. Onko-Sure® is a 96-well ELISA test kit sold to clinical reference labs. Labs run individual tests prescribed by doctors. Serum samples can be run, in duplicate, for 41 individuals, on each test kit.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radient's business metrics:

Radient's Business Metrics                                                  
Cash on hand: $372,255*                                                     
*Approximate amount as of October 19, 2011                                  
Common Shares Outstanding: 647 million*                                     
*Approximate number as of October 19, 2011.                                 
 750 million shares authorized.                                             
Outstanding Warrants & Options: 111 million*                                
*Approximate number as of October 19, 2011                                  

Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Digg this    Bookmark with del.icio.us    Add to Newsvine


Back to news